Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg)

What is Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg)?

The Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg), often shortened to Reta-Cagri, is a research co-formulation of two synthetic peptides in one lyophilised vial: retatrutide, a 39-amino-acid triple agonist of the GIP, GLP-1 and glucagon receptors, and cagrilintide, a long-acting acylated analogue of the 37-amino-acid hormone amylin that activates amylin and calcitonin receptors. Each vial contains 5mg of retatrutide and 5mg of cagrilintide.

Both components are investigational compounds and neither has been licensed as a medicine. The blend is designed for laboratories that want to explore whether amylin receptor signalling adds to the effects of a triple incretin agonist. GenoPept supplies the Retatrutide + Cagrilintide Blend as a research product for UK laboratories, strictly for in-vitro research use.

Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg) research applications

The rationale for co-investigating retatrutide and cagrilintide is that four distinct receptor systems are engaged at once. The preclinical research areas below are typical.

Multi-receptor energy balance models

Research explores whether adding amylin receptor activation to GIP, GLP-1 and glucagon receptor agonism produces additive effects on food intake, energy expenditure and body weight in diet-induced obesity models.

Satiety pathway cross-talk

The Retatrutide + Cagrilintide Blend is used to study interactions between amylin signalling in the area postrema and incretin signalling in the hypothalamus and hindbrain, including effects on neuronal activation markers.

Hepatic and adipose metabolism

Retatrutide’s glucagon receptor activity promotes hepatic fat oxidation, while cagrilintide slows gastric emptying and suppresses glucagon; research examines how these opposing and complementary actions net out in liver and adipose tissue readouts.

Benchmarking against other combinations

The blend allows comparison with the cagrilintide plus semaglutide pairing so that the incremental value of GIP and glucagon receptor activation can be assessed.

Mechanism of action (preclinical)

Retatrutide activates the GIP, GLP-1 and glucagon receptors, all class B G-protein-coupled receptors signalling through cAMP. GIP and GLP-1 receptor activation supports glucose-dependent insulin secretion and reduces food intake, while glucagon receptor activation increases hepatic lipid oxidation and energy expenditure in preclinical models.

Cagrilintide activates amylin receptors (calcitonin receptor and RAMP heterodimers) and the calcitonin receptor, reducing meal size and gastric emptying through brainstem circuits. Because amylin and incretin receptors are expressed in different neuronal populations, the combination is hypothesised to recruit non-overlapping satiety and metabolic pathways. Both peptides carry fatty diacid side chains that give comparable once-weekly pharmacokinetics in published studies.

Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg) product specifications

Available sizes

Retatrutide + Cagrilintide Blend is available in the following vial sizes:

• 10mg (5mg + 5mg) vial

Laboratories that need larger quantities can order in bulk boxes of 10 vials, which save 20–50% against single-vial pricing. Retail baskets also receive automatic discounts at £300, £500 and £1,000, and delivery is free on UK orders of £200 or more.

Reconstitution, handling and storage (laboratory)

Unopened Retatrutide + Cagrilintide Blend vials should be stored at −20 °C for long-term storage, or at 2–8 °C for short periods, and protected from light. Allow the vial to reach room temperature before opening to avoid condensation on the lyophilised cake.

To reconstitute for in-vitro work, add bacteriostatic water or another sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Do not shake, as agitation can damage large acylated peptides. Reconstituted solution should be kept at 2–8 °C and used within the period specified in the laboratory’s own protocol. See our guides on how to reconstitute research peptides and how to store research peptides for step-by-step handling notes.

Quality assurance and Certificate of Analysis

Every batch of Retatrutide + Cagrilintide Blend is tested by an independent third-party laboratory (Puralytix, ISO/IEC 17025 accredited) using HPLC for purity and LC-MS for identity confirmation. Results are published in a batch-specific Certificate of Analysis (COA), and each vial is labelled with its lot number and expiry date so the paperwork can be matched to the product on the bench.

Use the “View Certificate of Analysis” button on this page to open the current batch COA, or browse the full COA library. Our article on what a Certificate of Analysis shows explains how to read the chromatogram and mass spectrum.

Related research compounds

• Retatrutide: the triple agonist component, available alone for single-agent controls.
• Cagrilintide: the amylin analogue component in single-peptide vials.
• Cagrilintide + Semaglutide Blend: the comparator combination with a selective GLP-1 receptor agonist.
• Tirzepatide: a dual GIP/GLP-1 receptor agonist for further comparison work.

Retatrutide + Cagrilintide Blend 10mg (5mg + 5mg) frequently asked questions

What is the Retatrutide + Cagrilintide Blend used for in research?

The Retatrutide + Cagrilintide Blend is used in laboratories to study combined triple incretin and amylin receptor signalling. Preclinical research applies it to energy balance models, satiety pathway cross-talk studies, liver and adipose metabolism experiments, and benchmarking against other peptide combinations. It is supplied for in-vitro and animal-model research only, never for human or veterinary use.

How is the blend supplied and what is in each vial?

Each 10mg vial contains 5mg of retatrutide and 5mg of cagrilintide as lyophilised powder in a sealed, sterile glass vial with a black cap, labelled with lot number and expiry date. Purity of at least 99% and identity are confirmed for each batch by an independent ISO/IEC 17025 laboratory using HPLC and LC-MS, and the Certificate of Analysis is available from the product page.

How should the Retatrutide + Cagrilintide Blend be stored?

Store unopened vials at minus 20 degrees Celsius for long-term storage, or at 2 to 8 degrees Celsius for short periods, protected from light. After reconstitution with bacteriostatic water or sterile diluent, keep the solution refrigerated at 2 to 8 degrees Celsius and use it within the period defined by your laboratory protocol.

Is the Retatrutide + Cagrilintide Blend for human use?

No. The Retatrutide + Cagrilintide Blend supplied by GenoPept is strictly for in-vitro laboratory research. Both components are investigational compounds, not licensed medicines, and the product must not be used for human or veterinary purposes, diagnosis or treatment. Purchasers are responsible for complying with UK research use only requirements and institutional policies.

How does Reta-Cagri differ from the Cagrilintide + Semaglutide Blend?

Both blends pair cagrilintide with an incretin-type peptide, but Reta-Cagri uses retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist, whereas the other blend uses semaglutide, a selective GLP-1 receptor agonist. Researchers compare the two to assess whether GIP and glucagon receptor activation add to amylin-based effects in preclinical models. Each Reta-Cagri vial contains 5mg of each peptide.

Research use only. Retatrutide + Cagrilintide Blend is supplied by GenoPept strictly for in-vitro laboratory research. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. Read our research use only policy and UK legal guide before ordering.